Anzeige
Erschienen in:
11.09.2017 | Original Article – Clinical Oncology
Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia
Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2017
Einloggen, um Zugang zu erhaltenAbstract
Purpose
To explore health-related quality-of-life (HRQoL) profiles and identify socio-demographic and clinical variables associated with HRQoL in persons with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs).
Methods
A cross-sectional questionnaire was distributed to adults with chronic-phase CML receiving tyrosine kinase-inhibitor (TKI) therapy >3 months in complete cytogenetic response (CCyR). Respondents were anonymous. SF-36 Health Survey was used to measure HRQoL.
Results
Data from 828 respondents were analyzable. 524 (63%) were male. Median age was 42 years (range 18–88 years). 648 (78%) were receiving imatinib. Median TKI-therapy duration was 36 months (range 3–178 months). 638 (77%) paid some or all of their TKI costs. Annual out-of-pocket expenses >$4600 USD was associated with lower physical component summary (PCS; −2.8 to −3.8; P = 0.0081 and 0.0009) and mental component summary (MCS; −2.1 to −4.3; P = 0.0394 and 0.0080) in multivariate analyses. Other variables significantly associated with a lower PCS and/or MCS included: (1) female sex; (2) increasing age; (3) education level < bachelor degree; (4) co-morbidity(ies); and (5) generic drug use. TKI-therapy duration 3–5 years was associated with higher PCS and MCS.
Conclusions
Higher out-of-pocket expense for TKI therapy is significantly associated with worse HRQoL in persons with chronic-phase CML in CCyR receiving TKI therapy. These data indicate the importance of drug cost and health insurance policies on people’s HRQoL.